FDA Schedules ODAC Meetings to Review Pending Drug Applications

August 06, 2022

The FDA has scheduled 3 sessions for the Oncologic Drugs Advisory Committee to review updates on the new drug application for poziotinib tablets and data for the continued approval of indications for melphalan flufenamide and duvelisib.

Adkins Discusses Benefit of Second-line CAR T-Cell Therapy in Large B-Cell Lymphoma

August 04, 2022

Sherry Adkins, MSN, ANP-C, discusses the significance of incorporating CAR T-cell therapy regimens, such as lisocabtagene autoleucel, into earlier lines of treatment for patients with relapsed/refractory large B-cell lymphoma.

Addition of Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression, Death in DLBCL

July 23, 2022

Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.

Axi-cel Linked To Longer Quality Time Without Toxicity in Patients With R/R LBCL

July 22, 2022

A quality time without symptoms of toxicities analysis of the pivotal ZUMA-7 trial found that patients with relapsed or refractory large B-cell lymphoma experienced longer time without toxicity with axicabtagene ciloleucel than with standard of care.

Mosunetuzumab Receives Priority Review Designation for Relapsed/Refractory Follicular Lymphoma

July 22, 2022

Mosunetuzumab, a CD20 and CD3 T-cell engaging bispecific antibody, received a priority review designation from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma following at least 2 prior systemic therapies.